Recent research led to development of a cumulative genetic risk score for Takayasu arteritis, identifying differing susceptibility between groups with different genetic ancestries.
The year before my hike, I was extremely busy with various ACR workforce issues; meetings; presentations, locally, regionally and nationally; juggling medical missions and more. However, I had blocked time in my calendar over one year in advance to hike the Camino de Santiago in Spain with a long-time U.S. Army buddy. I met Pat…
Although dryness and other symptoms of Sjögren’s disease continue to vex patients, the prospect of new treatments and a recent name change demonstrate advances in patient care.
Matthew J. Mandell, DO, FACP, Yishui Chen, MD, Prerna Rastogi, MD, PhD, & Rebecca Tuetken, MD, PhD |
Syphilis, an ancient disease caused by the spirochete Treponema pallidum, has been historically referred to as the great mimicker given its heterogenous presentation. Both systemic lupus erythematosus (SLE) and syphilis can have multi-systemic involvement. Both parvovirus B19 and syphilis have been reported to cause histologic features similar to those seen in lupus nephritis. We present…
On May 6, more than 100 members of the rheumatology community participated in 118 meetings with lawmakers from 26 states—urging members of Congress to sustain research funding, address cuts and stabilize Medicare reimbursement, enact pharmacy benefit manager (PBM) reforms and protect Medicaid funding. See photos and stories from the event.
For the 2024 Image Competition, the ACR sought images with educational or remarkable manifestations representing a diverse range of pediatric patients with autoimmune, inflammatory, infectious and malignant drivers of rheumatic disease. Here, we showcase the winning images from South Asia.
Many rheumatology researchers share concerns about the landscape for future opportunities, given recent pressures from the current presidential administration. These may make an already challenging environment even more difficult for academic physicians to successfully navigate. But many in the field will persevere despite obstacles, driven by the need to deepen understanding of these conditions and…
Based on research showing improved signs and symptoms of systemic sclerosis in patients taking cilnidipine vs. placebo, the FDA granted orphan drug designation for the agent.